European Journal of Cancer
Volume 46, Issue 5 , Pages 892-900 , March 2010

17ß-Hydroxysteroid dehydrogenase type 1 as predictor of tamoxifen response in premenopausal breast cancer

  • Ann-Christine Källström

      Affiliations

    • Department of Surgery, Helsingborg Hospital, Sweden
    • Division of Oncology, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linköping University, Sweden
    • Corresponding Author InformationCorresponding author: Address: Department of Surgery, Helsingborgs Lasarett, SE-251 87 Helsingborg, Sweden. Tel.: +46 42 4061481; fax: +46 42 4063659.
    • ,
  • Rebecka Salme

      Affiliations

    • Division of Oncology, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linköping University, Sweden
    • ,
  • Lisa Rydén

      Affiliations

    • Department of Surgery, Institution of Clinical Sciences, Lund University, Sweden
    • ,
  • Bo Nordenskjöld

      Affiliations

    • Division of Oncology, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linköping University, Sweden
    • ,
  • Per-Ebbe Jönsson

      Affiliations

    • Department of Surgery, Helsingborg Hospital, Sweden
    • Institution of Clinical Sciences, Lund University, Malmö, Sweden
    • ,
  • Olle Stål

      Affiliations

    • Division of Oncology, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linköping University, Sweden

Received 24 September 2009 ,Revised 4 December 2009 ,Accepted 9 December 2009.

References 

  1. McGuire WL. Current status of estrogen receptors in human breast cancer. Cancer. 1975;36:638–644
  2. Hawkins RA, Oakey RE. Estimation of oestrone sulphate, oestradiol-17beta and oestrone in peripheral plasma: concentrations during the menstrual cycle and in men. J Endocrinol. 1974;60:3–17
  3. Sasano H, Suzuki T, Nakata T, Moriya T. New development in intracrinology of breast carcinoma. Breast Cancer. 2006;13:129–136
  4. Pasqualini JR, Chetrite GS. Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer. J Steroid Biochem Mol Biol. 2005;93:221–236
  5. Gunnarsson C, Olsson BM, Stal O. Abnormal expression of 17beta-hydroxysteroid dehydrogenases in breast cancer predicts late recurrence. Cancer Res. 2001;61:8448–8451
  6. Miyoshi Y, Ando A, Shiba E, et al. Involvement of up-regulation of 17beta-hydroxysteroid dehydrogenase type 1 in maintenance of intratumoral high estradiol levels in postmenopausal breast cancers. Int J Cancer. 2001;94:685–689
  7. Oduwole OO, Li Y, Isomaa VV, et al. 17Beta-hydroxysteroid dehydrogenase type 1 is an independent prognostic marker in breast cancer. Cancer Res. 2004;64:7604–7609
  8. Gunnarsson C, Hellqvist E, Stal O. 17Beta-hydroxysteroid dehydrogenases involved in local oestrogen synthesis have prognostic significance in breast cancer. Brit J Cancer. 2005;92:547–552
  9. Jansson A, Delander L, Gunnarsson C, et al. Ratio of 17HSD1 to 17HSD2 protein expression predicts the outcome of tamoxifen treatment in postmenopausal breast cancer patients. Clin Cancer Res. 2009;15:3610–3616
  10. Peltoketo H, Isomaa V, Poutanen M, Vihko R. Expression and regulation of 17 beta-hydroxysteroid dehydrogenase type 1. J Endocrinol. 1996;150(Suppl):S21–S30
  11. Luu-The V, Zhang Y, Poirier D, Labrie F. Characteristics of human types 1, 2 and 3 17 beta-hydroxysteroid dehydrogenase activities: oxidation/reduction and inhibition. J Steroid Biochem Mol Biol. 1995;55:581–587
  12. Miettinen MM, Mustonen MV, Poutanen MH, Isomaa VV, Vihko RK. Human 17 beta-hydroxysteroid dehydrogenase type 1 and type 2 isoenzymes have opposite activities in cultured cells and characteristic cell- and tissue-specific expression. Biochem J. 1996;314:839–845
  13. Soderqvist G, Poutanen M, Wickman M, et al. 17Beta-hydroxysteroid dehydrogenase type 1 in normal breast tissue during the menstrual cycle and hormonal contraception. J Clin Endocrinol Metab. 1998;83:1190–1193
  14. Gunnarsson C, Jerevall PL, Hammar K, et al. Amplification of HSD17B1 has prognostic significance in postmenopausal breast cancer. Breast Cancer Res Treat. 2008;108:35–41
  15. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687–717.
  16. Ryden L, Jonsson PE, Chebil G, et al. Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial with long-term follow-up. Eur J Cancer. 2005;41:256–264
  17. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. Swedish Breast Cancer Cooperative Group. J Natl Cancer Inst 1996;88:1543–9.
  18. Ryden L, Landberg G, Stal O, et al. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information. Breast Cancer Res Treat. 2008;109:351–357
  19. Stendahl M, Ryden L, Nordenskjold B, et al. High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients. Clin Cancer Res. 2006;12:4614–4618
  20. Labrie F, Luu-The V, Labrie C, et al. Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev. 2003;24:152–182
  21. Nguyen BL, Chetrite G, Pasqualini JR. Transformation of estrone and estradiol in hormone-dependent and hormone-independent human breast cancer cells. Effects of the antiestrogen ICI 164, 384, danazol, and promegestone (R-5020). Breast Cancer Res Treat. 1995;34:139–146
  22. Poutanen M, Moncharmont B, Vihko R. 17Beta-hydroxysteroid dehydrogenase gene expression in human breast cancer cells: regulation of expression by a progestin. Cancer Res. 1992;52:290–294
  23. Suzuki T, Moriya T, Ariga N, et al. 17Beta-hydroxysteroid dehydrogenase type 1 and type 2 in human breast carcinoma: a correlation to clinicopathological parameters. Brit J Cancer. 2000;82:518–523
  24. Cui X, Schiff R, Arpino G, Osborne CK, Lee AV. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol. 2005;23:7721–7735
  25. Yang S, Fang Z, Gurates B, et al. Stromal PRs mediate induction of 17beta-hydroxysteroid dehydrogenase type 2 expression in human endometrial epithelium: a paracrine mechanism for inactivation of E2. Mol Endocrinol. 2001;2093–2105
  26. Pasqualini JR. Differential effects of progestins on breast tissue enzymes. Maturitas. 2003;46:S45–S54
  27. Mustonen MV, Isomaa VV, Vaskivuo T, et al. Human 17beta-hydroxysteroid dehydrogenase type 2 messenger ribonucleic acid expression and localization in term placenta and in endometrium during the menstrual cycle. J Clin Endocrinol Metab. 1998;83:1319–1324
  28. Kitawaki J, Koshiba H, Ishihara H, et al. Progesterone induction of 17beta-hydroxysteroid dehydrogenase type 2 during the secretory phase occurs in the endometrium of estrogen-dependent benign diseases but not in normal endometrium. J Clin Endocrinol Metab. 2000;85:3292–3296
  29. Dowsett M, Cuzick J, Wale C, et al. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J Clin Oncol. 2005;23:7512–7517
  30. Day JM, Tutill HJ, Purohit A, Reed MJ. Design and validation of specific inhibitors of 17beta-hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis. Endocr Relat Cancer. 2008;15:665–692

PII: S0959-8049(09)00928-9

doi: 10.1016/j.ejca.2009.12.016

European Journal of Cancer
Volume 46, Issue 5 , Pages 892-900 , March 2010

Article Tools

* Image Usage & Resolution